PRESCIENT THERAPEUTICS LIMITED - Announcements

Market Cap $31.40M Add to my watchlist

Healthcare Biotechnology

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

PTX	March 2024 Quarterly Update and Appendix 4C	PRICE SENSITIVE	30/04/24	392.22KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	23/02/24	656.43KB	Share
PTX	December 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/01/24	2.53MB	Share
PTX	PTX-100 Ph1b results show excellent safety & efficacy in TCL	PRICE SENSITIVE	11/12/23	1.3MB	Share
PTX	September 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/10/23	1.32MB	Share
PTX	Appendix 4E and 2023 Annual Report	PRICE SENSITIVE	25/08/23	1.24MB	Share
PTX	June 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	27/07/23	6.49MB	Share
PTX	March 2023 Quarterly Update and Appendix 4C	PRICE SENSITIVE	28/04/23	1.53MB	Share
PTX	Continued promising results in PTX-100 TCL trial	PRICE SENSITIVE	16/03/23	2.08MB	Share
PTX	FDA grants broader orphan drug status to PTX100 for TCLs	PRICE SENSITIVE	09/03/23	893.45KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	24/02/23	1.58MB	Share
PTX	December 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	25/01/23	1.19MB	Share
PTX	AGM Presentation	PRICE SENSITIVE	29/11/22	2.43MB	Share
PTX	September 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/10/22	1.37MB	Share
PTX	PTX-100 Trial Update	PRICE SENSITIVE	25/10/22	4.01MB	Share
PTX	Placement Results	PRICE SENSITIVE	11/10/22	691.74KB	Share
PTX	SPP Results and Placement	PRICE SENSITIVE	07/10/22	883.36KB	Share
PTX	Trading Halt	PRICE SENSITIVE	07/10/22	861.26KB	Share
PTX	PTX unveils CellPryme-A to boost CAR-T performance	PRICE SENSITIVE	23/09/22	1.8MB	Share
PTX	PTX strategic collaboration with MD Anderson Cancer Center	PRICE SENSITIVE	07/09/22	894.66KB	Share
PTX	Prescient Therapeutics Launches Share Purchase Plan	PRICE SENSITIVE	24/08/22	831.85KB	Share
PTX	Appendix 4E and 2022 Annual Report	PRICE SENSITIVE	23/08/22	2.06MB	Share
PTX	PTX agreement with Thermo Fisher for scalable OmniCAR	PRICE SENSITIVE	18/08/22	695.52KB	Share
PTX	PTX OmniCAR cell manufacturing contract for clinical trials	PRICE SENSITIVE	16/08/22	673.53KB	Share
PTX	June 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	25/07/22	1.24MB	Share
PTX	US FDA Grants Orphan Drug Designation to PTX-100 for PTCL	PRICE SENSITIVE	15/07/22	299.4KB	Share
PTX	Key OmniCAR Patent Granted in US	PRICE SENSITIVE	05/07/22	525.88KB	Share
PTX	PTX CellPryme-M presentation	PRICE SENSITIVE	08/06/22	7.35MB	Share
PTX	PTX unveils new clinic-ready CAR-T enhancement platform	PRICE SENSITIVE	08/06/22	1.19MB	Share
PTX	PTX-200 AML expansion after another complete response	PRICE SENSITIVE	09/05/22	1.11MB	Share
PTX	March 2022 Quarterly Update and Appendix 4C	PRICE SENSITIVE	29/04/22	706.28KB	Share
PTX	Recruitment Open for Expansion Cohort of Phase 1B Study	PRICE SENSITIVE	05/04/22	1.04MB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	25/02/22	447.78KB	Share
PTX	December 2021 Quarterly Update and Appendix 4C	PRICE SENSITIVE	31/01/22	426.4KB	Share
PTX	September 2021 Quarterly Activities and Appendix 4C	PRICE SENSITIVE	28/10/21	417.33KB	Share
PTX	Investor Presentation - October 2021	PRICE SENSITIVE	13/10/21	2.75MB	Share
PTX	PTX data demonstrates key OmniCAR features in next gen CAR-T	PRICE SENSITIVE	13/10/21	631.85KB	Share
PTX	Appendix 4E and 2021 Annual Report	PRICE SENSITIVE	30/08/21	1.34MB	Share
PTX	June 2021 Quarterly Activities and Appendix 4C	PRICE SENSITIVE	30/07/21	393.29KB	Share
PTX	PTX-100 trial advances following successful Phase 1b	PRICE SENSITIVE	27/07/21	384.64KB	Share
PTX	PTX successful immunogenicity testing of OmniCAR	PRICE SENSITIVE	05/07/21	364.06KB	Share
PTX	PTX Completes CAR-T Manufacturing Milestone for OmniCAR	PRICE SENSITIVE	24/06/21	393.66KB	Share
PTX	Response to ASX Price Query	PRICE SENSITIVE	03/06/21	404.55KB	Share
PTX	PTX signs CAR-T agreement with Peter MacCallum	PRICE SENSITIVE	10/05/21	306.4KB	Share
PTX	March 2021 Quarterly Update and Appendix 4C	PRICE SENSITIVE	29/04/21	215.54KB	Share
PTX	PTX-200 AML Trial Progresses to Higher Dose	PRICE SENSITIVE	23/04/21	344.35KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	24/02/21	798.25KB	Share
PTX	December 2020 Quarterly Update and Appendix 4C	PRICE SENSITIVE	28/01/21	314.36KB	Share
PTX	PTX announces 3 next-gen CAR-T programs with OmniCAR	PRICE SENSITIVE	18/01/21	1.91MB	Share
PTX	AGM Presentation	PRICE SENSITIVE	24/11/20	2.08MB	Share
PTX	Prescient Receives $1.03m R&D Tax Rebate	PRICE SENSITIVE	11/11/20	298.41KB	Share
PTX	September 2020 Quarterly Update and Appendix 4C	PRICE SENSITIVE	20/10/20	183.81KB	Share
PTX	Response to ASX Query	PRICE SENSITIVE	16/09/20	335.57KB	Share
PTX	PTX Raises $7 million via Strongly Supported Placement	PRICE SENSITIVE	26/08/20	147KB	Share
PTX	Appendix 4E and 2020 Annual Report	PRICE SENSITIVE	25/08/20	1.06MB	Share
PTX	Successful SPP Closed Early	PRICE SENSITIVE	18/08/20	146.86KB	Share
PTX	Extension of Share Purchase Plan	PRICE SENSITIVE	14/08/20	137.09KB	Share
PTX	PTX Announces Cell Therapy Collaboration with Peter Mac	PRICE SENSITIVE	14/08/20	145.5KB	Share
PTX	PTX-100 progresses to next cohort in basket clinical study	PRICE SENSITIVE	12/08/20	175.99KB	Share
PTX	PTX-200 AML Trial Progresses to Next Dose Level	PRICE SENSITIVE	03/08/20	133.1KB	Share
PTX	Prescient Therapeutics Launches Share Purchase Plan	PRICE SENSITIVE	27/07/20	137.29KB	Share
PTX	Trading Halt	PRICE SENSITIVE	24/07/20	186.08KB	Share
PTX	June 2020 Quarterly Update and Appendix 4C	PRICE SENSITIVE	22/07/20	227.48KB	Share
PTX	2 PTX Assets Chosen in Doherty Institute COVID-19 Program	PRICE SENSITIVE	21/07/20	143.57KB	Share
PTX	Trading Halt	PRICE SENSITIVE	20/07/20	219.28KB	Share
PTX	Trading Pause	PRICE SENSITIVE	20/07/20	115.51KB	Share
PTX	Reinstatement to Official Quotation	PRICE SENSITIVE	26/05/20	86.1KB	Share
PTX	PTX signs next-gen anti-cancer platform from Penn & Oxford	PRICE SENSITIVE	26/05/20	333.74KB	Share
PTX	Voluntary Suspension	PRICE SENSITIVE	25/05/20	177.44KB	Share
PTX	Trading Halt	PRICE SENSITIVE	21/05/20	203.68KB	Share
PTX	Pause in Trading	PRICE SENSITIVE	21/05/20	116.53KB	Share
PTX	PTX-100 progresses to new dose, adds new site	PRICE SENSITIVE	22/04/20	187.29KB	Share
PTX	March 2020 Quarterly Update and Appendix 4C	PRICE SENSITIVE	16/04/20	269.84KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	28/02/20	455.36KB	Share
PTX	December 2019 Appendix 4C - Quarterly	PRICE SENSITIVE	31/01/20	200.41KB	Share
PTX	PTX-200 High Overall Response in Ph2a Breast Cancer trial	PRICE SENSITIVE	23/12/19	165.58KB	Share
PTX	Encouraging data from PTX-200 ovarian cancer trial	PRICE SENSITIVE	12/12/19	179.19KB	Share
PTX	Third complete response in PTX-200 AML Trial	PRICE SENSITIVE	27/11/19	140.39KB	Share
PTX	Response to ASX Price Query	PRICE SENSITIVE	22/11/19	618.64KB	Share
PTX	PTX in new CAR-T collaboration	PRICE SENSITIVE	18/11/19	156.13KB	Share
PTX	1st patient dosed in trial for first in class drug PTX-100	PRICE SENSITIVE	14/11/19	149.8KB	Share
PTX	Receipt of R&D Tax Rebate	PRICE SENSITIVE	08/11/19	125.33KB	Share
PTX	Prescient Ausbiotech Ras Presentation	PRICE SENSITIVE	31/10/19	1.49MB	Share
PTX	September 2019 Appendix 4C - Quarterly	PRICE SENSITIVE	30/10/19	286.49KB	Share
PTX	Appendix 4E and 2019 Annual Report	PRICE SENSITIVE	26/08/19	1.27MB	Share
PTX	June 2019 Appendix 4C - Quarterly	PRICE SENSITIVE	24/07/19	197.38KB	Share
PTX	PTX Initiates Phase 1b Clinical Trial for PTX-100	PRICE SENSITIVE	11/07/19	162.13KB	Share
PTX	Change to Exercise Price of Options	PRICE SENSITIVE	30/05/19	103.71KB	Share
PTX	Canadian Patent Granted for PTX-200	PRICE SENSITIVE	16/05/19	105.28KB	Share
PTX	Entitlement Offer Results and Shortfall Notification	PRICE SENSITIVE	26/04/19	133.61KB	Share
PTX	March 2019 Appendix 4C - Quarterly	PRICE SENSITIVE	24/04/19	371.99KB	Share
PTX	Despatch of Entitlement Offer Documents	PRICE SENSITIVE	03/04/19	671.2KB	Share
PTX	Prospectus	PRICE SENSITIVE	25/03/19	593.04KB	Share
PTX	Capital Raising Presentation - March 2019	PRICE SENSITIVE	25/03/19	1.46MB	Share
PTX	Prescient Completes Equity Raising to Raise $9.1 Million	PRICE SENSITIVE	25/03/19	234.12KB	Share
PTX	Trading Halt	PRICE SENSITIVE	21/03/19	366.13KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	21/02/19	588.55KB	Share
PTX	December 2018 Appendix 4C - Quarterly	PRICE SENSITIVE	31/01/19	203.56KB	Share
PTX	Receipt of R&D Tax Rebate	PRICE SENSITIVE	15/01/19	115.61KB	Share
PTX	Interim Durability Analysis of PTX-200 Breast Cancer Study	PRICE SENSITIVE	10/12/18	119.14KB	Share

PTX March 2024 Quarterly Update and Appendix 4C
30/04/24	PRICE SENSITIVE	392.22KB	Share
PTX Appendix 4D and Half Year Financial Report
23/02/24	PRICE SENSITIVE	656.43KB	Share
PTX December 2023 Quarterly Update and Appendix 4C
31/01/24	PRICE SENSITIVE	2.53MB	Share
PTX PTX-100 Ph1b results show excellent safety & efficacy in TCL
11/12/23	PRICE SENSITIVE	1.3MB	Share
PTX September 2023 Quarterly Update and Appendix 4C
31/10/23	PRICE SENSITIVE	1.32MB	Share
PTX Appendix 4E and 2023 Annual Report
25/08/23	PRICE SENSITIVE	1.24MB	Share
PTX June 2023 Quarterly Update and Appendix 4C
27/07/23	PRICE SENSITIVE	6.49MB	Share
PTX March 2023 Quarterly Update and Appendix 4C
28/04/23	PRICE SENSITIVE	1.53MB	Share
PTX Continued promising results in PTX-100 TCL trial
16/03/23	PRICE SENSITIVE	2.08MB	Share
PTX FDA grants broader orphan drug status to PTX100 for TCLs
09/03/23	PRICE SENSITIVE	893.45KB	Share
PTX Appendix 4D and Half Year Financial Report
24/02/23	PRICE SENSITIVE	1.58MB	Share
PTX December 2022 Quarterly Update and Appendix 4C
25/01/23	PRICE SENSITIVE	1.19MB	Share
PTX AGM Presentation
29/11/22	PRICE SENSITIVE	2.43MB	Share
PTX September 2022 Quarterly Update and Appendix 4C
31/10/22	PRICE SENSITIVE	1.37MB	Share
PTX PTX-100 Trial Update
25/10/22	PRICE SENSITIVE	4.01MB	Share
PTX Placement Results
11/10/22	PRICE SENSITIVE	691.74KB	Share
PTX SPP Results and Placement
07/10/22	PRICE SENSITIVE	883.36KB	Share
PTX Trading Halt
07/10/22	PRICE SENSITIVE	861.26KB	Share
PTX PTX unveils CellPryme-A to boost CAR-T performance
23/09/22	PRICE SENSITIVE	1.8MB	Share
PTX PTX strategic collaboration with MD Anderson Cancer Center
07/09/22	PRICE SENSITIVE	894.66KB	Share
PTX Prescient Therapeutics Launches Share Purchase Plan
24/08/22	PRICE SENSITIVE	831.85KB	Share
PTX Appendix 4E and 2022 Annual Report
23/08/22	PRICE SENSITIVE	2.06MB	Share
PTX PTX agreement with Thermo Fisher for scalable OmniCAR
18/08/22	PRICE SENSITIVE	695.52KB	Share
PTX PTX OmniCAR cell manufacturing contract for clinical trials
16/08/22	PRICE SENSITIVE	673.53KB	Share
PTX June 2022 Quarterly Update and Appendix 4C
25/07/22	PRICE SENSITIVE	1.24MB	Share
PTX US FDA Grants Orphan Drug Designation to PTX-100 for PTCL
15/07/22	PRICE SENSITIVE	299.4KB	Share
PTX Key OmniCAR Patent Granted in US
05/07/22	PRICE SENSITIVE	525.88KB	Share
PTX PTX CellPryme-M presentation
08/06/22	PRICE SENSITIVE	7.35MB	Share
PTX PTX unveils new clinic-ready CAR-T enhancement platform
08/06/22	PRICE SENSITIVE	1.19MB	Share
PTX PTX-200 AML expansion after another complete response
09/05/22	PRICE SENSITIVE	1.11MB	Share
PTX March 2022 Quarterly Update and Appendix 4C
29/04/22	PRICE SENSITIVE	706.28KB	Share
PTX Recruitment Open for Expansion Cohort of Phase 1B Study
05/04/22	PRICE SENSITIVE	1.04MB	Share
PTX Appendix 4D and Half Year Financial Report
25/02/22	PRICE SENSITIVE	447.78KB	Share
PTX December 2021 Quarterly Update and Appendix 4C
31/01/22	PRICE SENSITIVE	426.4KB	Share
PTX September 2021 Quarterly Activities and Appendix 4C
28/10/21	PRICE SENSITIVE	417.33KB	Share
PTX Investor Presentation - October 2021
13/10/21	PRICE SENSITIVE	2.75MB	Share
PTX PTX data demonstrates key OmniCAR features in next gen CAR-T
13/10/21	PRICE SENSITIVE	631.85KB	Share
PTX Appendix 4E and 2021 Annual Report
30/08/21	PRICE SENSITIVE	1.34MB	Share
PTX June 2021 Quarterly Activities and Appendix 4C
30/07/21	PRICE SENSITIVE	393.29KB	Share
PTX PTX-100 trial advances following successful Phase 1b
27/07/21	PRICE SENSITIVE	384.64KB	Share
PTX PTX successful immunogenicity testing of OmniCAR
05/07/21	PRICE SENSITIVE	364.06KB	Share
PTX PTX Completes CAR-T Manufacturing Milestone for OmniCAR
24/06/21	PRICE SENSITIVE	393.66KB	Share
PTX Response to ASX Price Query
03/06/21	PRICE SENSITIVE	404.55KB	Share
PTX PTX signs CAR-T agreement with Peter MacCallum
10/05/21	PRICE SENSITIVE	306.4KB	Share
PTX March 2021 Quarterly Update and Appendix 4C
29/04/21	PRICE SENSITIVE	215.54KB	Share
PTX PTX-200 AML Trial Progresses to Higher Dose
23/04/21	PRICE SENSITIVE	344.35KB	Share
PTX Appendix 4D and Half Year Financial Report
24/02/21	PRICE SENSITIVE	798.25KB	Share
PTX December 2020 Quarterly Update and Appendix 4C
28/01/21	PRICE SENSITIVE	314.36KB	Share
PTX PTX announces 3 next-gen CAR-T programs with OmniCAR
18/01/21	PRICE SENSITIVE	1.91MB	Share
PTX AGM Presentation
24/11/20	PRICE SENSITIVE	2.08MB	Share
PTX Prescient Receives $1.03m R&D Tax Rebate
11/11/20	PRICE SENSITIVE	298.41KB	Share
PTX September 2020 Quarterly Update and Appendix 4C
20/10/20	PRICE SENSITIVE	183.81KB	Share
PTX Response to ASX Query
16/09/20	PRICE SENSITIVE	335.57KB	Share
PTX PTX Raises $7 million via Strongly Supported Placement
26/08/20	PRICE SENSITIVE	147KB	Share
PTX Appendix 4E and 2020 Annual Report
25/08/20	PRICE SENSITIVE	1.06MB	Share
PTX Successful SPP Closed Early
18/08/20	PRICE SENSITIVE	146.86KB	Share
PTX Extension of Share Purchase Plan
14/08/20	PRICE SENSITIVE	137.09KB	Share
PTX PTX Announces Cell Therapy Collaboration with Peter Mac
14/08/20	PRICE SENSITIVE	145.5KB	Share
PTX PTX-100 progresses to next cohort in basket clinical study
12/08/20	PRICE SENSITIVE	175.99KB	Share
PTX PTX-200 AML Trial Progresses to Next Dose Level
03/08/20	PRICE SENSITIVE	133.1KB	Share
PTX Prescient Therapeutics Launches Share Purchase Plan
27/07/20	PRICE SENSITIVE	137.29KB	Share
PTX Trading Halt
24/07/20	PRICE SENSITIVE	186.08KB	Share
PTX June 2020 Quarterly Update and Appendix 4C
22/07/20	PRICE SENSITIVE	227.48KB	Share
PTX 2 PTX Assets Chosen in Doherty Institute COVID-19 Program
21/07/20	PRICE SENSITIVE	143.57KB	Share
PTX Trading Halt
20/07/20	PRICE SENSITIVE	219.28KB	Share
PTX Trading Pause
20/07/20	PRICE SENSITIVE	115.51KB	Share
PTX Reinstatement to Official Quotation
26/05/20	PRICE SENSITIVE	86.1KB	Share
PTX PTX signs next-gen anti-cancer platform from Penn & Oxford
26/05/20	PRICE SENSITIVE	333.74KB	Share
PTX Voluntary Suspension
25/05/20	PRICE SENSITIVE	177.44KB	Share
PTX Trading Halt
21/05/20	PRICE SENSITIVE	203.68KB	Share
PTX Pause in Trading
21/05/20	PRICE SENSITIVE	116.53KB	Share
PTX PTX-100 progresses to new dose, adds new site
22/04/20	PRICE SENSITIVE	187.29KB	Share
PTX March 2020 Quarterly Update and Appendix 4C
16/04/20	PRICE SENSITIVE	269.84KB	Share
PTX Appendix 4D and Half Year Financial Report
28/02/20	PRICE SENSITIVE	455.36KB	Share
PTX December 2019 Appendix 4C - Quarterly
31/01/20	PRICE SENSITIVE	200.41KB	Share
PTX PTX-200 High Overall Response in Ph2a Breast Cancer trial
23/12/19	PRICE SENSITIVE	165.58KB	Share
PTX Encouraging data from PTX-200 ovarian cancer trial
12/12/19	PRICE SENSITIVE	179.19KB	Share
PTX Third complete response in PTX-200 AML Trial
27/11/19	PRICE SENSITIVE	140.39KB	Share
PTX Response to ASX Price Query
22/11/19	PRICE SENSITIVE	618.64KB	Share
PTX PTX in new CAR-T collaboration
18/11/19	PRICE SENSITIVE	156.13KB	Share
PTX 1st patient dosed in trial for first in class drug PTX-100
14/11/19	PRICE SENSITIVE	149.8KB	Share
PTX Receipt of R&D Tax Rebate
08/11/19	PRICE SENSITIVE	125.33KB	Share
PTX Prescient Ausbiotech Ras Presentation
31/10/19	PRICE SENSITIVE	1.49MB	Share
PTX September 2019 Appendix 4C - Quarterly
30/10/19	PRICE SENSITIVE	286.49KB	Share
PTX Appendix 4E and 2019 Annual Report
26/08/19	PRICE SENSITIVE	1.27MB	Share
PTX June 2019 Appendix 4C - Quarterly
24/07/19	PRICE SENSITIVE	197.38KB	Share
PTX PTX Initiates Phase 1b Clinical Trial for PTX-100
11/07/19	PRICE SENSITIVE	162.13KB	Share
PTX Change to Exercise Price of Options
30/05/19	PRICE SENSITIVE	103.71KB	Share
PTX Canadian Patent Granted for PTX-200
16/05/19	PRICE SENSITIVE	105.28KB	Share
PTX Entitlement Offer Results and Shortfall Notification
26/04/19	PRICE SENSITIVE	133.61KB	Share
PTX March 2019 Appendix 4C - Quarterly
24/04/19	PRICE SENSITIVE	371.99KB	Share
PTX Despatch of Entitlement Offer Documents
03/04/19	PRICE SENSITIVE	671.2KB	Share
PTX Prospectus
25/03/19	PRICE SENSITIVE	593.04KB	Share
PTX Capital Raising Presentation - March 2019
25/03/19	PRICE SENSITIVE	1.46MB	Share
PTX Prescient Completes Equity Raising to Raise $9.1 Million
25/03/19	PRICE SENSITIVE	234.12KB	Share
PTX Trading Halt
21/03/19	PRICE SENSITIVE	366.13KB	Share
PTX Appendix 4D and Half Year Financial Report
21/02/19	PRICE SENSITIVE	588.55KB	Share
PTX December 2018 Appendix 4C - Quarterly
31/01/19	PRICE SENSITIVE	203.56KB	Share
PTX Receipt of R&D Tax Rebate
15/01/19	PRICE SENSITIVE	115.61KB	Share
PTX Interim Durability Analysis of PTX-200 Breast Cancer Study
10/12/18	PRICE SENSITIVE	119.14KB	Share

REFRESH

(20min delay)
Last 3.9¢		Change -0.003(7.14%)		Mkt cap ! $31.40M

Open	High	Low	Value	Volume
4.0¢	4.1¢	3.9¢	$75.11K	1.897M

Buyers (Bids)

No.	Vol.	Price($)
2	355874	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	75	1

View Market Depth

No.	Vol.	Price($)
2	355874	0.039
6	700788	0.038
3	80513	0.037
4	399500	0.036
4	298576	0.035

Price($)	Vol.	No.
0.040	75	1
0.041	230198	2
0.042	350000	2
0.043	247971	2
0.044	100000	1

Last trade - 15.59pm 19/06/2024 (20 minute delay)


Last 4.0¢		Change -0.003 ( 2.44 %)
Open	High	Low	Volume
4.0¢	4.1¢	4.0¢	733248
Last updated 15.59pm 19/06/2024 ?

PTX (ASX) Chart

PRESCIENT THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories